Suppr超能文献

整合病毒清除策略——反思现状,展望未来。

Integrated viral clearance strategies-reflecting on the present, projecting to the future.

机构信息

Merck & Co., Inc., Biologics and Vaccines, Downstream Process Development and Engineering Department, Kenilworth, NJ 07033, USA.

出版信息

Curr Opin Biotechnol. 2018 Oct;53:137-143. doi: 10.1016/j.copbio.2018.01.003. Epub 2018 Jan 23.

Abstract

Viral clearance and inactivation are critical steps in ensuring the safety of biological products derived from mammalian cell culture and are a component of an adventitious agent control strategy which spans both upstream and downstream processes. Although these approaches have been sufficient to support the development of biologics to date, the empirical and semi-quantitative nature of the approach leaves some potential gaps. For example, the concept of performing a quantitative risk assessment for the downstream components of virus safety was introduced in ICH Q5A for XMuLV. An ideal future state would be to perform a similar quantitative risk assessment for a range of viruses based on an assessment of potential virus risk in both upstream and downstream processes. This assessment combined with an integrated control strategy (including monitoring) would be extremely beneficial in minimizing potential adventitious agent risks. Significant progress has been achieved towards this goal in the last several years including recent advances in quantification of virus sequences in cell banks (ADVTIG), development of truly modular or generic viral clearance claims for specific unit operations, enhanced controls of upstream media (HTST/nanofiltration) and the use of RVLP for in-process monitoring. The recent shift towards continuous processing has the potential to enhance the criticality of in-line monitoring and the complexity of viral clearance and inactivation (owing to a wide range of potential 'worst case' viral clearance scenarios). However, gaps exist in, firstly, the ability to quantify potential virus risk levels in process streams in real-time, secondly, mechanistic understanding of virus/chromatography media interactions, and thirdly, mechanistic understanding of virus/filter interactions. Some new technologies may also need to be developed to allow for real-time confirmation of virus inactivation and clearance to support process development (both batch and continuous) and assessment of the impact of process deviations during manufacturing. This review paper provides an overview of the current state of an overall integrated control strategy for upstream and downstream processing and highlights the investments that could be pursued to achieve the future state of a quantitative virus risk assessment for a range of viruses. One potential approach to address these gaps is the use of data mining from large, comprehensive and diverse data sets to establish heuristic rules for virus detection, clearance and inactivation followed by specific hypothesis-driven experiments for cases that fall outside of the normal paradigm. Once this approach reaches a mature state suitable for implementation, there is an opportunity to update regulatory guidance (e.g. ICH Q5A) accordingly.

摘要

病毒清除和失活是确保哺乳动物细胞培养衍生的生物制品安全性的关键步骤,也是涵盖上下游工艺的外源因子控制策略的组成部分。尽管这些方法迄今为止足以支持生物技术的发展,但该方法的经验性和半定量性质仍存在一些潜在的差距。例如,在 ICH Q5A 中提出了对病毒安全性的下游组件进行定量风险评估的概念。理想的未来状态是基于对上下游工艺中潜在病毒风险的评估,对一系列病毒进行类似的定量风险评估。这种评估与综合控制策略(包括监测)相结合,将非常有利于最大限度地降低潜在的外源因子风险。在过去几年中,已经在朝着这一目标取得重大进展,包括最近在细胞库中病毒序列的定量方面的进展(ADVTIG)、为特定单元操作开发真正模块化或通用的病毒清除声明、上游介质的增强控制(HTST/纳米过滤)和使用 RVLP 进行过程监测。最近向连续加工的转变有可能增强在线监测的重要性以及病毒清除和失活的复杂性(由于潜在的“最坏情况”病毒清除场景范围广泛)。然而,目前仍然存在一些差距,首先是实时定量过程流中潜在病毒风险水平的能力,其次是病毒/色谱介质相互作用的机制理解,以及病毒/过滤器相互作用的机制理解。可能还需要开发一些新技术,以便实时确认病毒失活和清除,以支持工艺开发(批处理和连续)并评估生产过程中工艺偏差的影响。本文综述了上下游工艺整体综合控制策略的现状,强调了为实现对一系列病毒进行定量病毒风险评估的未来状态而可以进行的投资。解决这些差距的一种潜在方法是使用来自大型、综合和多样化数据集的数据挖掘来建立病毒检测、清除和失活的启发式规则,然后针对超出正常范例的情况进行具体的假设驱动实验。一旦这种方法达到适合实施的成熟状态,就有机会相应地更新监管指南(例如 ICH Q5A)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验